Abstract 4117
Background
ITM (defined as intralymphatic local, satellite, and regional cutaneous/subcutaneous metastases) is associated with significant morbidity; optimal therapy is poorly defined. T-VEC is an oncolytic immunotherapy approved for melanoma treatment based on results from the phase III OPTiM trial. This retrospective analysis of OPTiM assessed T-VEC in pts with unresectable AJCC 7 stage IIIB/C melanoma who had LR disease, including ITM, as the site of first recurrence following primary surgery.
Methods
In OPTiM, pts were randomised to intralesional T-VEC or subcutaneous recombinant GM-CSF. All pts were treated for ≥6 months, after which treatment was continued until clinically relevant disease progression, intolerability, consent withdrawal, complete response (CR), lack of response by 1 yr, or disappearance of injectable lesions (T-VEC arm only).
Results
109 patients (T-VEC n = 79; GM-CSF n = 30) had LR disease as the site of first recurrence (including ITM, local surgical scar, and regional lymph nodes). Most pts (63%) had ITM. Median time from primary melanoma diagnosis to first LR recurrence was 10.4 months. Time from first recurrence to randomisation into OPTiM was 6.6 months. At primary diagnosis, 45% of 109 pts had melanoma in the lower limbs, 25% in the head/neck, 15% on the trunk, and 11% upper limbs. At baseline, median age was 65 yrs, 94% had LDH ≤ULN, 76% had ECOG PS 0 and 35% had nodular melanoma. T-VEC vs GM-CSF led to objective response rates of 56% vs 1%, CR rates of 24% vs 0%, and durable response rates of 34% vs 0% (all p < 0.002 vs GM-CSF). Median OS was not reached with T-VEC vs 25 months with GM-CSF (HR, 0.48; 95% CI, 0.28–0.84; p = 0.0088). The LR subpopulation experienced higher T-VEC efficacy vs the entire study population (Table).Table:
1342P
Outcome | OPTiM locoregional subpopulation, incl. ITM* | OPTiM overall study population (ITT; stage IIIB-IVM1c melanoma) | ||||
---|---|---|---|---|---|---|
T-VEC (n = 79) | GM-CSF (n = 30) | Difference (p value or 95% CI) | T-VEC (n = 295) | GM-CSF (n = 141) | Difference (p value or 95% CI) | |
Objective response rate, % (n) | 56 (44) | 3 (1) | 52.4 (p < 0.0001) | 26 (78) | 6 (8) | 20.8 (p < 0.01) |
Complete response, % (n) | 24 (19) | 0 (0) | 24.1 (p < 0.0015) | 11 (32) | <1 (1) | 10.1 (p < 0.0001) |
Durable response rate (response for ≥6 consecutive months), % (n) | 34 (27) | 0 (0) | 34.2 (p < 0.0001) | 16 (48) | 2 (3) | 14.1 (p < 0.001) |
Deaths, % (n) | 42 (33) | 67 (20) | HR: 0.48 (p = 0.0088) | 64 (189) | 72 (101) | HR: 0.79(0=0.051) |
OS probability at landmark times (KM estimate), % 1 year 2 years 3 years 4 years | 92 75 62 52 | 80 50 40 30 | 12.4 (-3.1, 27.9) 24.7 (4.4, 45.0) 21.9 (1.3, 42.4) 22.8 (-0.6, 46.2) | 74 50 39 33 | 69 40 30 21 | 4.6 (-4.7, 13.8) 9.5 (-0.5, 19.6) 8.5 (-1.2, 18.1) 11.3 (1.0, 21.5) |
Grouped term including in-transit/satellitosis (ITM), local surgical scar, and regional lymph nodes (LNs). 59 pts had ITM only as the site of 1st recurrence, 17 had regional LNs only, 20 had surgical scar only, 2 had ITM AND regional LNs, 3 had surgical scar AND regional LNs, 5 had ITM AND surgical scar, and 3 pts had ITM, regional LNs AND surgical scar as the sites of 1st recurrence.
HR, hazard ratio; ITT, intent-to-treat; KM, Kaplan-Meier; NR, not reported; OS, overall survival.
Conclusions
This analysis suggests that T-VEC may be of particular benefit in melanoma pts with LR recurrence, including ITM.
Clinical trial identification
NCT00769704.
Editorial acknowledgement
Ryan Woodrow, PhD, CMPP of Aspire Scientific (Bollington, UK), funded by Amgen (Europe) GmbH (Rotkreuz, Switzerland).
Legal entity responsible for the study
Amgen Inc.
Funding
Amgen Inc.
Disclosure
M.R. Middleton: Advisory / Consultancy, Research grant / Funding (institution): Amgen; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Eisai; Advisory / Consultancy, Research grant / Funding (institution): GlaxoSmithKline; Advisory / Consultancy, Research grant / Funding (institution): Immunocore; Advisory / Consultancy: Lilly; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Millennium; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Physiomics; Advisory / Consultancy, Research grant / Funding (institution): Rigontec; Advisory / Consultancy, Research grant / Funding (institution): Roche; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Clovis; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Vertex; Advisory / Consultancy, Research grant / Funding (institution): Amgen; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Eisai; Advisory / Consultancy, Research grant / Funding (institution): GlaxoSmithKline; Advisory / Consultancy, Research grant / Funding (institution): Immunocore; Advisory / Consultancy: Lilly; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Millennium; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Physiomics; Advisory / Consultancy, Research grant / Funding (institution): Rigontec; Advisory / Consultancy, Research grant / Funding (institution): Roche; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Clovis; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Vertex. K. Harrington: Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Advisory / Consultancy: Pfizer; Speaker Bureau / Expert testimony, Research grant / Funding (institution): MSD. M. Ross: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck ; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen. K. Ohrling: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen. H. Radcliffe: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen. F. Collichio: Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Merck.
Resources from the same session
5579 - Quality of informed consent in clinical trials patients
Presenter: Gianluca Catania
Session: Poster Display session 3
Resources:
Abstract
5147 - Patient's rights: Where do we stand?
Presenter: Maja Kozuh
Session: Poster Display session 3
Resources:
Abstract
1279 - The oncology nurse coordinator’s role in a digestive oncology department: Impact on patient and hospital
Presenter: Fouad Awada
Session: Poster Display session 3
Resources:
Abstract
1670 - Nursing model for a breast cancer unit at the Catalan Institute of Oncology
Presenter: Ana Rodriguez-ortega
Session: Poster Display session 3
Resources:
Abstract
3936 - Role of cancer nurse in the prevention and control of acute deterioration for oncohematologic patient
Presenter: Raquel Azor Portolés
Session: Poster Display session 3
Resources:
Abstract
2789 - Standardized nursing care in the department of radiotherapy of a network of cancer centres
Presenter: José Delgado
Session: Poster Display session 3
Resources:
Abstract
4482 - Exploring anxiety, depression and quality of life of ambulatory cancer patients during chemotherapy.
Presenter: Theodoula Adamakidou
Session: Poster Display session 3
Resources:
Abstract
3075 - Implementing a Cancer Survivorship Program for Individuals with Recurrent Breast Cancer
Presenter: Darcy Burbage
Session: Poster Display session 3
Resources:
Abstract
3869 - The perceptions of parents/guardians regarding their child/adolescent’s experience of reflexology or non-specific foot massage The perceptions of parents/guardians regarding their child/adolescents experience of reflexology or non-specific foot massage
Presenter: Patricia Fox
Session: Poster Display session 3
Resources:
Abstract
4064 - Quality of life in survivors of adult haematological malignancies
Presenter: Anita Immanuel
Session: Poster Display session 3
Resources:
Abstract